The efficacy and safety of a new Russian HIV non-nucleoside reverse transcriptase inhibitor (VM-1500, Elpivirine) as a component in an antiretroviral therapy regimen
- Authors: Kravchenko A.V1, Orlova-Morozova E.A2, Shimonova T.E3, Kozyrev O.A4, Nagimova F.I5, Bychko V.V6, Vostokova N.V7, Zozulya O.V7
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Moscow Regional Center for Prevention and Control of AIDS and Infectious Diseases
- infectious Diseases Hospital Two, Moscow Healthcare Department
- Volgograd Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Republican Center for Prevention and Control of AIDS and Infectious Diseases, Ministry of Health of the Republic of Tatarstan
- OOO «Viriom»
- OOO «INFARMA»
- Issue: No 5 (2015)
- Pages: 58-64
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278333
- ID: 278333
Cite item
Abstract
Full Text
About the authors
A. V Kravchenko
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: kravtchenko@hivmssia.net
Moscow
E. A Orlova-Morozova
Moscow Regional Center for Prevention and Control of AIDS and Infectious Diseases
Email: orlovamorozova@gmail.com
T. E Shimonova
infectious Diseases Hospital Two, Moscow Healthcare Department
O. A Kozyrev
Volgograd Regional Center for Prevention and Control of AIDS and Infectious Diseases
Email: volghiv@mail.ru
F. I Nagimova
Republican Center for Prevention and Control of AIDS and Infectious Diseases, Ministry of Health of the Republic of Tatarstan
Email: nagimova@list.ru
Kazan
V. V Bychko
OOO «Viriom»
Email: vbichko@viriom.com
Khimki, Moscow Region
N. V Vostokova
OOO «INFARMA»
Email: nv@ipharma.ru
Khimki, Moscow Region
O. V Zozulya
OOO «INFARMA»
Email: ovz@ipharma.ru
Khimki, Moscow Region
References
- Guidelinesfor the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.1; November, 2014). European AIDS Clinical Society. http://www.eacsociety.net
- Guidelinesfor the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). April 8, 2015. http:// www. AIDSinfo.nih.gov
- Cohen C., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378(9787): 229- 237. DOI: http://dx.doi.org/10.1016/S0140-6736(11)60983-5
- Molina J-M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., Boven K., on behalf of the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378(9787): 238-246. DOI: http://dx.doi.org/10.1016/S0140-6736(11)60936-7.
- Канестри В.Г., Кравченко А.В., Ганкина Н.Ю. Гепатотоксичность антиреровирусной терапии больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; 1: 31-36.
- Ratanasuwan W., Werarak P., Murphy R.L., Bichko V. A randomized, placebo-controlled, double-blind study ofVM-1500 in HIV-naïve patients. The Conference on Retroviruses and Opportunistic Infectious (CROI), Boston, MA, USA, 2014: Abstr. 544LB.